OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia, June 1, 2015  -- OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI - News) announced that results from an exploratory analysis of the Phase 2  Borealis-1™ trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.  Patients in the trial with a Karnofsky Performance Status (KPS) of 80 percent or less, a common indicator of poor prognosis, experienced a 50 percent reduction in risk of death with the addition of apatorsen therapy (OS HR = 0.50). These results were presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Published: 01 June 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: OncoGenex Pharmaceuticals Inc ( OGXI )

Ignyta Announces Phase 1 Clinical Trial Data for Entrectinib

Well tolerated, with no drug-related serious adverse events
Recommended Phase 2 dose determined
91% response rate in patients meeting expected Phase 2 eligibility criteria

SAN DIEGO--- Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that interim results from the company’s two Phase 1 clinical trials of entrectinib were presented in poster presentations, including a poster discussion, at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Entrectinib is the company’s proprietary oral tyrosine kinase inhibitor targeting tumors that harbor activating alterations to NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1 or ALK.

Published: 01 June 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Ignyta Inc ( RXDX )

ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer

Objective response rate (ORR) of 53% – as single agent – in patients with folate-receptor alpha (FRα)-positive platinum-resistant ovarian cancer. Majority of responses are ongoing. Clinical development program advancing, expanding.

WALTHAM, Mass.-- ImmunoGen, Inc. (IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting of the first clinical findings in a disease-specific patient population with the Company’s unique, FRα-targeting ADC, mirvetuximab soravtansine (abstract #5518).

Published: 01 June 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: ImmunoGen Inc ( IMGN )

Heron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL®

-Primary endpoint achieved
-SUSTOL, as part of a three-drug regimen, is the first 5-HT3 antagonist to demonstrate superiority to standard-of-care for delayed nausea and vomiting after HEC
-SUSTOL-based regimen was associated with significantly reduced nausea and improved patient satisfaction
-Conference call and webcast Friday, May 29 at 8:30 A.M. ET

REDWOOD CITY, Calif.-- Heron Therapeutics, Inc. (HRTX) today announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Company’s 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.

Published: 29 May 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Heron Therapeutics Inc ( HRTX )

BriaCell to Partner With Top U.S. Medical Institution Washington University to Produce Its BriaVax(TM) Cancer Vaccine

VANCOUVER, BC--(May 27, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT), an immuno-oncology focused biotechnology company with a proprietary vaccine technology (BriaVax™), is pleased to announce that it has just signed an LOI outlining a Manufacturing Partnership with Washington University in St. Louis and its Siteman Comprehensive Cancer Center ("Washington University" or "Siteman Comprehensive Cancer Center").

The proposed Manufacturing Partnership outlines terms through which Washington University's Siteman Comprehensive Cancer Center will produce BriaVax™ for BriaCell's anticipated clinical trial. Washington University will manufacture 300 vials of BriaVax™ utilizing its Current Good Manufacturing Practice; otherwise known as a cGMP Facility.

Published: 27 May 2015
Written by Editor
Up on News   Project Update  
Read more: BriaCell Therapeutics Corp ( BCT )
  1. Actinium Pharmaceuticals Inc ( ATNM )
  2. Intellipharmaceutics International ( I / IPCI )
  3. Prima BioMed Ltd ( PBMD )
  4. Cellular Biomedicine Group Inc ( CBMG )
  5. Ampio Pharmaceuticals Inc ( AMPE )